Difference between revisions of "Part:BBa K4279001"
| Line 14: | Line 14: | ||
== Usage and Biology == | == Usage and Biology == | ||
BBa_K4279000 is the coding sequence of SP-lipase. Lipase is a primary lipase critical for triacylglyceride digestion in humans and is considered a promising target for the treatment of obesity [1]. Triacylglycerol lipase is the primary lipase secreted by the pancreas, and is responsible for breaking down dietary lipids into unesterified fatty acids (FAs) and monoglycerides (MGs). Medically, lipases are targets for therapeutic intervention in the treatment of obesity. The focus of applied research with lipases has been to exploit the unusual properties of lipolytic systems for the production of chiral pharmaceuticals, improved detergents, and designer fats [2]. Obesity is a medical condition in which excess body fat accumulates to the extent that it may have a negative effect on health, leading to reduced life expectancy and/or increased health problems. Diverse approaches to the prevention and treatment of obesity have been reported [3-5]. W1-lipase (EC 3.1.1.3) is a lipase amplified from Pseudomonas sp. 7323. The SP-lipase is made up of 265 aa [6]. | BBa_K4279000 is the coding sequence of SP-lipase. Lipase is a primary lipase critical for triacylglyceride digestion in humans and is considered a promising target for the treatment of obesity [1]. Triacylglycerol lipase is the primary lipase secreted by the pancreas, and is responsible for breaking down dietary lipids into unesterified fatty acids (FAs) and monoglycerides (MGs). Medically, lipases are targets for therapeutic intervention in the treatment of obesity. The focus of applied research with lipases has been to exploit the unusual properties of lipolytic systems for the production of chiral pharmaceuticals, improved detergents, and designer fats [2]. Obesity is a medical condition in which excess body fat accumulates to the extent that it may have a negative effect on health, leading to reduced life expectancy and/or increased health problems. Diverse approaches to the prevention and treatment of obesity have been reported [3-5]. W1-lipase (EC 3.1.1.3) is a lipase amplified from Pseudomonas sp. 7323. The SP-lipase is made up of 265 aa [6]. | ||
| − | + | [[File:BBa K4279001-figure1.png|500px|thumb|center|Figure 1. The structural modeling of an extremophilic bacterial lipase isolated from saline habitats..]] | |
| − | + | ||
| + | |||
<!-- --> | <!-- --> | ||
Revision as of 08:08, 26 September 2022
W1-lipase
W1-lipase
Profile
Name: SP-lipase
Base Pairs: 1854 bp
Origin: Lactiplantibacillus Plantarum, genome
Properties: a lipase for triacylglyceride digestion.
Usage and Biology
BBa_K4279000 is the coding sequence of SP-lipase. Lipase is a primary lipase critical for triacylglyceride digestion in humans and is considered a promising target for the treatment of obesity [1]. Triacylglycerol lipase is the primary lipase secreted by the pancreas, and is responsible for breaking down dietary lipids into unesterified fatty acids (FAs) and monoglycerides (MGs). Medically, lipases are targets for therapeutic intervention in the treatment of obesity. The focus of applied research with lipases has been to exploit the unusual properties of lipolytic systems for the production of chiral pharmaceuticals, improved detergents, and designer fats [2]. Obesity is a medical condition in which excess body fat accumulates to the extent that it may have a negative effect on health, leading to reduced life expectancy and/or increased health problems. Diverse approaches to the prevention and treatment of obesity have been reported [3-5]. W1-lipase (EC 3.1.1.3) is a lipase amplified from Pseudomonas sp. 7323. The SP-lipase is made up of 265 aa [6].
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 777
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal AgeI site found at 46
- 1000COMPATIBLE WITH RFC[1000]